Navigation Links
Prostate cancer therapy increases risk of fractures and cardiovascular-related death
Date:4/26/2009

Prostate cancer patients who undergo therapy to decrease testosterone levels increase their risk of developing bone- and heart-related side effects compared to patients who do not take these medications, according to a new analysis. Published in the June 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that preventive measures and careful scrutiny of patients' health can keep men from experiencing these potentially serious consequences.

While medical treatments that decrease testosterone levelscalled androgen deprivation therapy (ADT)are important and effective therapies for men with prostate cancer, they can cause a variety of side effects including skeletal and cardiovascular complications, sexual dysfunction, periodontal disease, and mood disorders.

Bone and heart complications are among the most serious side effects associated with ADT, but the actual risk patients have of developing these effects is unknown. Lockwood Taylor, MPH, of the University of Texas Health Science Center and colleagues conducted a study to assess this risk by analyzing all of the literature related to side effects from ADT published between 1996 and mid-2008. They found 14 studies (8 bone-related, 6 heart-related) that were suitable for analysis.

The researchers' review revealed that men treated with ADT for prostate cancer had an increased risk of bone fractures and heart-related death, although the absolute risk for both was still low. For bone fractures, there was a 23 percent increased risk compared to prostate cancer patients who did not undergo the treatment. The absolute risk of fracture among ADT-exposed men was still only 7.2 per 100 person years. For heart-related death, the increased risk among ADT-exposed men was 17 percent higher compared to other prostate cancer patients. However, because the baseline risk is low, the increase translated to an additional one-to-two deaths per 1,000 men who received ADT. Two large studies also documented significant increases in diabetes risk associated with the therapy.

"While the absolute risks of fracture and cardiovascular mortality are low among men treated with androgen deprivation therapy, preventive treatments may further reduce the risk of these serious adverse outcomes related to androgen deprivation therapy," the authors wrote. They also noted that because some patients may benefit from this therapy more than others, physicians should consider each patient's overall health and prostate cancer status when weighing treatment options.


'/>"/>

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society
Source:Eurekalert

Related medicine news :

1. Statins Guard Against Prostate Cancer
2. Statins may exert influence on prostate cancer growth by reducing inflammation
3. Major statin study reveals several important findings for reducing prostate cancer and disease
4. Varian Medical Systems to Exhibit Full Spectrum of Prostate Cancer Treatment Technologies at the American Urological Association Meeting in Chicago
5. Agent Orange Exposure Tied to Prostate Cancer Return
6. Harvard Medical School Prostate Disease Website Guides Patients Through Decision-Making Process
7. MRI: Effective tool for determining pathologic stage of prostate cancer
8. Preoperative MR may assist surgeons in nerve sparing during robotic prostatectomy
9. CyberKnife Radiosurgery Used to Treat More Than 3,000 Prostate Cancer Patients Worldwide
10. InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer
11. Science Makes Inroads Against Prostate, Other Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Liposuction specialist Marcia V. Byrd, ... St. Louis, Missouri at the Marriot St. Louis Airport Hotel. This year’s conference was ... address the conference about her unique specialization in treating Lipedema. Dr. Byrd is considered ...
(Date:5/5/2016)... ... , ... Is the part in your hair widening? Are you finding more ... a good opportunity to raise awareness about a common condition among women: hair loss. ... women experience hair loss or ‘thinning’ by the time they reach menopause, but many ...
(Date:5/4/2016)... ... 04, 2016 , ... ProList is a set of 30 self-animating bullet points ... editors can easily create lists for presentations, youtube productions, and more. Simply choose ... is the perfect complement to presentation style videos. , ProList is a package of ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... and interview techniques, seeks to add a deeper understanding of the program, policy ... weaknesses, and each answers different yet important questions. , In a new brief ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... Business Conference. The conference opened on Tuesday with Frank Luntz, sharing a dynamic, ... PDMP Solution provided a deep dive on NCPDP’s model solution to help stem ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... York , May 4, 2016 ... Transparency Market Research entitled "Brain Computer Interface Market - Global ... - 2024," the  global brain computer interface (BCI) market  is ... 2024. The market is estimated to expand at a ... 2016 to 2024. A BCI device provides ...
(Date:5/4/2016)... NESS ZIONA, Israel , May ... BVXV, TASE: BVXV) announced today that BiondVax,s CEO, Dr. ... 2016 conference in New York City . ... presenting at 10:30am at Pioneers 2016, a conference presented by ... New York Palace Hotel. The BiondVax presentation that ...
(Date:5/4/2016)... -- Yissum Research Development Company of ... it had signed an exclusive world-wide licensing and research ... protein degradation and immunomodulatory drugs for cancer and immune ... representing first-in-class therapy for hematologic and solid malignancies. Financial ... The novel technology was developed by Yinon Ben-Neriah ...
Breaking Medicine Technology: